image
Healthcare - Drug Manufacturers - Specialty & Generic - NASDAQ - US
$ 6.29
0.347 %
$ 336 M
Market Cap
-10.14
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Apr, 22, 2025.

The intrinsic value of one TKNO stock under the worst case scenario is HIDDEN Compared to the current market price of 6.29 USD, Alpha Teknova, Inc. is HIDDEN

This DCF valuation model was last updated on Apr, 22, 2025.

The intrinsic value of one TKNO stock under the base case scenario is HIDDEN Compared to the current market price of 6.29 USD, Alpha Teknova, Inc. is HIDDEN

This DCF valuation model was last updated on Apr, 22, 2025.

The intrinsic value of one TKNO stock under the best case scenario is HIDDEN Compared to the current market price of 6.29 USD, Alpha Teknova, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart TKNO

image
$10.0$10.0$9.0$9.0$8.0$8.0$7.0$7.0$6.0$6.0$5.0$5.0$4.0$4.0Nov '24Nov '2415 Nov15 NovDec '24Dec '2415 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 Apr
FINANCIALS
37.7 M REVENUE
2.89%
-26.1 M OPERATING INCOME
26.48%
-26.7 M NET INCOME
27.28%
-12.4 M OPERATING CASH FLOW
34.14%
-27.3 M INVESTING CASH FLOW
-252.53%
14.9 M FINANCING CASH FLOW
16.34%
9.26 M REVENUE
-3.25%
-5.63 M OPERATING INCOME
24.27%
-5.72 M NET INCOME
24.40%
-936 K OPERATING CASH FLOW
54.54%
-1.41 M INVESTING CASH FLOW
94.51%
-87 K FINANCING CASH FLOW
-0.57%
Balance Sheet Alpha Teknova, Inc.
image
Current Assets 42.8 M
Cash & Short-Term Investments 30.4 M
Receivables 4.31 M
Other Current Assets 8.07 M
Non-Current Assets 76 M
Long-Term Investments 0
PP&E 61.5 M
Other Non-Current Assets 14.5 M
25.59 %3.63 %6.79 %51.80 %12.19 %Total Assets$118.8m
Current Liabilities 11.2 M
Accounts Payable 825 K
Short-Term Debt 5.84 M
Other Current Liabilities 4.54 M
Non-Current Liabilities 25.2 M
Long-Term Debt 14.9 M
Other Non-Current Liabilities 10.3 M
16.07 %12.48 %40.92 %28.26 %Total Liabilities$36.4m
EFFICIENCY
Earnings Waterfall Alpha Teknova, Inc.
image
Revenue 37.7 M
Cost Of Revenue 30.5 M
Gross Profit 7.23 M
Operating Expenses 33.4 M
Operating Income -26.1 M
Other Expenses 599 K
Net Income -26.7 M
40m40m30m30m20m20m10m10m00(10m)(10m)(20m)(20m)(30m)(30m)38m(31m)7m(33m)(26m)(599k)(27m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
19.16% GROSS MARGIN
19.16%
-69.27% OPERATING MARGIN
-69.27%
-70.86% NET MARGIN
-70.86%
-32.46% ROE
-32.46%
-22.52% ROA
-22.52%
-22.98% ROIC
-22.98%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Alpha Teknova, Inc.
image
00(10m)(10m)(20m)(20m)(30m)(30m)(40m)(40m)(50m)(50m)(60m)(60m)202020202021202120222022202320232024202420252025
Net Income -26.7 M
Depreciation & Amortization 6.58 M
Capital Expenditures -1.12 M
Stock-Based Compensation 3.67 M
Change in Working Capital -873 K
Others 741 K
Free Cash Flow -13.5 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Alpha Teknova, Inc.
image
TKNO has no price targets from Wall Street.
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 8
6. Ownership
Insider Ownership Alpha Teknova, Inc.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
15.1 M USD 3
9-12 MONTHS
7. News
Teknova and Pluristyx Launch Proprietary PluriFreeze™ Cryopreservation System to Accelerate the Development of Cell Therapies HOLLISTER, Calif., March 19, 2025 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), and Pluristyx, Inc., today announced that Pluristyx's PluriFreeze™ cryopreservation system is available for purchase exclusively from Teknova. globenewswire.com - 1 month ago
Teknova and Pluristyx Announce Collaboration to Streamline the Manufacture of Next-Generation Cell Therapies Teknova to Become the Exclusive Manufacturer and Distributor of Pluristyx's Novel PluriFreeze™ Cryopreservation System Teknova to Become the Exclusive Manufacturer and Distributor of Pluristyx's Novel PluriFreeze™ Cryopreservation System globenewswire.com - 1 month ago
Alpha Teknova, Inc. (TKNO) Q4 2024 Earnings Call Transcript Alpha Teknova, Inc. (NASDAQ:TKNO ) Q4 2024 Earnings Call March 4, 2025 5:00 PM ET Company Participants Jennifer Henry - Senior Vice President, Marketing Stephen Gunstream - President and Chief Executive Officer Matt Lowell - Chief Financial Officer Conference Call Participants Matt Larew - William Blair Matthew Parisi - KeyBanc Capital Markets Mark Massaro - BTIG Matt Hewitt - Craig-Hallum Operator Thank you for standing by, and welcome to Teknova's Fourth Quarter and Full Year 2024 Earnings Conference Call. [Operator Instructions] I would now like to hand the call over to Jennifer Henry, Senior Vice President of Marketing. seekingalpha.com - 1 month ago
Teknova Reports Fourth Quarter and Full Year 2024 Financial Results Full year 2024 total revenue was $37.7 million, up 3% year-over-year and in line with guidance Fourth quarter 2024 total revenue was $9.3 million, up 18% over the same quarter prior year Company provides 2025 revenue guidance of $39-42 million globenewswire.com - 1 month ago
Teknova to Report Fourth Quarter and Full Year 2024 Financial Results on March 4, 2025 HOLLISTER, Calif., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced that the Company will report its financial results for the fourth quarter and full year ended December 31, 2024, on Tuesday, March 4, 2025, following the close of market. globenewswire.com - 2 months ago
Alpha Teknova, Inc. (TKNO) Q3 2024 Earnings Call Transcript Alpha Teknova, Inc. (NASDAQ:TKNO ) Q3 2024 Earnings Conference Call November 7, 2024 5:30 PM ET Company Participants Jennifer Henry – Senior Vice President-Marketing Stephen Gunstream – President and Chief Executive Officer Matt Lowell – Chief Financial Officer Conference Call Participants Chad Wiatrowski – TD Cowen Lucas Baranowski – KeyBanc Capital Markets Vidyun Bais – BTIG Jacob Johnson – Stephens Matt Larew – William Blair Operator Hello, and welcome to Alpha Teknova Third Quarter 2024 Financial Results. At this time all participants are in a listen-only mode. seekingalpha.com - 5 months ago
Teknova Reports Third Quarter 2024 Financial Results Third quarter 2024 total revenue was $9.6 million, up 17% over the same quarter prior year Company lowers 2024 total free cash outflow outlook to less than $16 million Company reaffirms 2024 revenue guidance of $35-38 million globenewswire.com - 5 months ago
Teknova to Report Third Quarter 2024 Financial Results on November 7, 2024 HOLLISTER, Calif., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced that the Company will report its financial results for the third quarter ended September 30, 2024, on Thursday, November 7, 2024, following the close of market. globenewswire.com - 6 months ago
What Makes Alpha Teknova (TKNO) a Strong Momentum Stock: Buy Now? Does Alpha Teknova (TKNO) have what it takes to be a top stock pick for momentum investors? Let's find out. zacks.com - 6 months ago
Alpha Teknova, Inc. (TKNO) Q2 2024 Earnings Call Transcript Alpha Teknova, Inc. (NASDAQ:TKNO ) Q2 2024 Earnings Conference Call August 13, 2024 5:00 PM ET Company Participants Jennifer Henry - SVP, Marketing Stephen Gunstream - President & CEO Matt Lowell - CFO Conference Call Participants Mark Massaro - BTIG Jacob Johnson - Stephens Steven Mah - TD Cowen Paul Knight - KeyBanc Matt Larew - William Blair Operator Good day and thank you for standing by. Welcome to the Teknova's Second Quarter 2024 Financial Results. seekingalpha.com - 8 months ago
Teknova Reports Second Quarter 2024 Financial Results Second quarter 2024 total revenue was $9.6 million, up 3% sequentially Raised $15.4 million of equity capital in July 2024 Launched two new offerings: Express-TekSM Production and RUO+ manufacturing grade Company reaffirms 2024 revenue guidance of $35-38 million globenewswire.com - 8 months ago
Teknova to Report Second Quarter 2024 Financial Results on August 13, 2024 HOLLISTER, Calif., July 30, 2024 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced that the Company will report its financial results for the second quarter ended June 30, 2024, on Tuesday, August 13, 2024, following the close of market. globenewswire.com - 9 months ago
8. Profile Summary

Alpha Teknova, Inc. TKNO

image
COUNTRY US
INDUSTRY Drug Manufacturers - Specialty & Generic
MARKET CAP $ 336 M
Dividend Yield 0.00%
Description Alpha Teknova, Inc. provides critical reagents for life sciences market in the United States and internationally. Its reagents enable the discovery, development, and production of biopharmaceutical products, such as drug therapies, novel vaccines, and molecular diagnostics. The company offers pre-poured media plates for cell growth and cloning; liquid cell culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification. It serves life sciences market, including pharmaceutical and biotechnology companies, contract development and manufacturing organizations, in vitro diagnostic franchises, and academic and government research institutions. The company was founded in 1996 and is headquartered in Hollister, California.
Contact 2290 Bert Drive, Hollister, CA, 95023 https://www.teknova.com
IPO Date June 25, 2021
Employees 173
Officers Ms. Jennifer Henry Senior Vice President of Marketing Mr. Matthew C. Lowell Chief Financial Officer Mr. Damon A. Terrill J.D. General Counsel, Chief Compliance Officer & Secretary Mr. Stephen Gunstream President, Chief Executive Officer & Director